The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
ADC Therapeutics(NYSE:ADCT) 
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical tria...
Website: http://www.adctherapeutics.com
Founded: 2011
CEO: Christopher John Martin
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
ADC Therapeutics Days Payable Outstanding ttm (DPO)
ADC Therapeutics Days Receivable Outstanding ttm (DSO)
ADC Therapeutics Days Inventory Outstanding ttm (DIO)
ADC Therapeutics Op Cashflow Per Share ttm
ADC Therapeutics Free Cashflow Per Share ttm
ADC Therapeutics Cash Per Share ttm
ADC Therapeutics P/S ratio ttm
ADC Therapeutics (GAAP) P/E ratio ttm
ADC Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.